Investors & Media

Ionis and AstraZeneca close deal to develop and commercialize eplontersen

CARLSBAD, Calif. , Dec. 29, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational antisense medicine for the

Read more
You are now leaving to visit